(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.61%.
Rezolute's earnings in 2026 is -$77,184,000.On average, 12 Wall Street analysts forecast RZLT's earnings for 2026 to be -$67,718,917, with the lowest RZLT earnings forecast at -$75,424,575, and the highest RZLT earnings forecast at -$47,708,315. On average, 12 Wall Street analysts forecast RZLT's earnings for 2027 to be -$63,657,451, with the lowest RZLT earnings forecast at -$89,055,522, and the highest RZLT earnings forecast at -$44,787,398.
In 2028, RZLT is forecast to generate -$25,221,889 in earnings, with the lowest earnings forecast at -$63,611,087 and the highest earnings forecast at $30,182,812.